Compare NeoGenomics Inc. Common Stock (NEO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NeoGenomics Inc. Common Stock vs Novavax Inc — how do they compare? NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B), while Novavax Inc trades at $12.44 (market cap $2.11B). The key difference: NeoGenomics Inc. Common Stock and Novavax Inc are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, NeoGenomics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| NEO | NVAX | |
|---|---|---|
Market Cap | $2.14B | $2.11B |
Volume | 2,228,400 | 8,376,831 |
Sector | Health | Health |
52-Week High | $19.91 | $12.82 |
52-Week Low | $7.19 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.44B | $1.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.
The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
